NASDAQ:VRTX - Vertex Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $290.59
  • Forecasted Upside: 34.22 %
  • Number of Analysts: 31
  • Breakdown:
  • 0 Sell Ratings
  • 8 Hold Ratings
  • 22 Buy Ratings
  • 1 Strong Buy Ratings
$216.50
▼ -1.37 (-0.63%)
1 month | 3 months | 12 months
Get New Vertex Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$290.59
▲ +34.22% Upside Potential
This price target is based on 31 analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $290.59, with a high forecast of $340.00 and a low forecast of $230.00. The average price target represents a 34.22% upside from the last price of $216.50.
Buy
The current consensus among 31 contributing investment analysts is to buy stock in Vertex Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 15 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/3/2019
  • 1 strong buy ratings
  • 12 buy ratings
  • 7 hold ratings
  • 0 sell ratings
9/1/2019
  • 1 strong buy ratings
  • 15 buy ratings
  • 8 hold ratings
  • 0 sell ratings
11/30/2019
  • 1 strong buy ratings
  • 16 buy ratings
  • 8 hold ratings
  • 0 sell ratings
2/28/2020
  • 1 strong buy ratings
  • 20 buy ratings
  • 8 hold ratings
  • 0 sell ratings
5/28/2020
  • 1 strong buy ratings
  • 20 buy ratings
  • 8 hold ratings
  • 0 sell ratings
8/26/2020
  • 1 strong buy ratings
  • 20 buy ratings
  • 8 hold ratings
  • 0 sell ratings
10/25/2020
  • 1 strong buy ratings
  • 22 buy ratings
  • 8 hold ratings
  • 0 sell ratings
11/24/2020

Latest Recommendations

  • 1 strong buy ratings
  • 22 buy ratings
  • 8 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2020Sanford C. BernsteinInitiated CoverageOutperform$275.00Low
i
11/1/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
i
10/30/2020Piper SandlerLower Price TargetOverweight$327.00 ➝ $307.00Low
i
10/30/2020Credit Suisse GroupLower Price TargetOutperform$292.00 ➝ $285.00Low
i
10/30/2020SVB LeerinkLower Price TargetMarket Perform$267.00 ➝ $257.00High
i
10/28/2020UBS GroupInitiated CoverageBuy$287.00Low
i
10/26/2020Needham & Company LLCReiterated RatingHoldMedium
i
10/19/2020Morgan StanleyLower Price TargetEqual Weight$281.00 ➝ $249.00Medium
i
10/15/2020TruistLower Price Target$330.00 ➝ $305.00High
i
10/15/2020SVB LeerinkLower Price TargetMarket Perform$283.00 ➝ $267.00High
i
10/13/2020Morgan StanleyLower Price TargetEqual Weight$300.00 ➝ $281.00Low
i
9/18/2020Maxim GroupReiterated RatingHoldHigh
i
8/24/2020SVB LeerinkBoost Price TargetNeutral ➝ Market Perform$274.00 ➝ $283.00Medium
i
7/31/2020Cantor FitzgeraldBoost Price TargetOverweight$293.00 ➝ $305.00High
i
Rating by Alethia Young at Cantor Fitzgerald
7/31/2020SVB LeerinkBoost Price TargetMarket Perform$263.00 ➝ $274.00High
i
7/31/2020HC WainwrightReiterated RatingBuy$295.00 ➝ $315.00High
i
7/31/2020Piper SandlerBoost Price TargetOverweight$302.00 ➝ $327.00High
i
Rating by Edward Tenthoff at Piper Sandler
7/20/2020Credit Suisse GroupBoost Price TargetOutperform$298.00 ➝ $328.00High
i
7/16/2020CowenBoost Price TargetOutperform$265.00 ➝ $300.00Low
i
7/14/2020Jefferies Financial GroupBoost Price TargetBuy$295.00 ➝ $340.00High
i
7/8/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$277.00 ➝ $300.00Medium
i
7/2/2020The Goldman Sachs GroupBoost Price TargetPositive ➝ Conviction-Buy$290.00 ➝ $330.00Low
i
6/24/2020SunTrust BanksBoost Price TargetBuy$285.00 ➝ $330.00High
i
6/12/2020CitigroupBoost Price TargetTop Pick ➝ Buy$305.00 ➝ $325.00Low
i
5/15/2020ArgusBoost Price TargetBuy$270.00 ➝ $320.00High
i
5/1/2020CitigroupBoost Price TargetBuy$265.00 ➝ $305.00Medium
i
4/30/2020Credit Suisse GroupReiterated RatingBuy$298.00Medium
i
Rating by Evan Seigerman at Credit Suisse Group AG
4/30/2020CfraBoost Price TargetBuy$286.00 ➝ $297.00Low
i
4/30/2020GuggenheimBoost Price TargetBuy$266.00 ➝ $290.00High
i
Rating by Whitney Ijem at Guggenheim
4/30/2020BMO Capital MarketsBoost Price TargetOutperform$279.00 ➝ $283.00High
i
4/30/2020Stifel NicolausBoost Price TargetBuy$275.00 ➝ $285.00High
i
4/30/2020OppenheimerBoost Price TargetOutperform$265.00 ➝ $305.00High
i
4/30/2020Morgan StanleyBoost Price TargetOverweight$258.00 ➝ $277.00High
i
4/30/2020SVB LeerinkBoost Price TargetMarket Perform$224.00 ➝ $263.00High
i
4/30/2020JMP SecuritiesBoost Price TargetMarket Outperform$255.00 ➝ $285.00High
i
4/30/2020HC WainwrightBoost Price TargetBuy$270.00 ➝ $295.00High
i
4/28/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$250.00 ➝ $260.00High
i
4/27/2020Piper SandlerReiterated RatingBuy$300.00High
i
Rating by Edward Tenthoff at Piper Sandler
4/15/2020Morgan StanleyBoost Price TargetOverweight$251.00 ➝ $258.00Medium
i
3/27/2020Piper SandlerReiterated RatingBuy$300.00High
i
Rating by Edward Tenthoff at Piper Sandler
3/12/2020Wolfe ResearchInitiated CoverageOutperform$282.00High
i
3/11/2020Cantor FitzgeraldReiterated RatingOverweight$262.00 ➝ $275.00Medium
i
3/4/2020BarclaysInitiated CoverageOverweight$271.00High
i
3/3/2020CowenReiterated RatingBuy$260.00Medium
i
Rating by Phil Nadeau at Cowen Inc
3/2/2020ArgusBoost Price TargetPositive ➝ Buy$248.00 ➝ $270.00High
i
2/2/2020Evercore ISIReiterated RatingHold$270.00Medium
i
1/31/2020Piper SandlerBoost Price Target$284.00 ➝ $300.00Medium
i
1/31/2020Bank of AmericaReiterated RatingBuy$250.00 ➝ $295.00High
i
1/31/2020Needham & Company LLCReiterated RatingHoldHigh
i
1/31/2020Morgan StanleyBoost Price TargetOverweight$250.00 ➝ $251.00Low
i
Rating by Matthew Harrison at Morgan Stanley
1/31/2020Stifel NicolausBoost Price TargetBuy$243.00 ➝ $275.00High
i
1/31/2020Royal Bank of CanadaBoost Price TargetOutperform$240.00 ➝ $260.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
1/31/2020CfraBoost Price TargetBuy$237.00 ➝ $286.00High
i
1/31/2020Credit Suisse GroupBoost Price TargetOutperform$253.00 ➝ $258.00High
i
Rating by Evan Seigerman at Credit Suisse Group AG
1/31/2020SunTrust BanksReiterated RatingBuy$285.00High
i
1/31/2020JPMorgan Chase & Co.Boost Price TargetOverweight$247.00 ➝ $260.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/31/2020HC WainwrightBoost Price TargetBuy$220.00 ➝ $270.00High
i
1/31/2020Robert W. BairdDowngradeOutperform ➝ Neutral$210.00 ➝ $230.00High
i
Rating by Brian Skorney at Robert W. Baird
1/14/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/9/2020BMO Capital MarketsBoost Price Target$248.00 ➝ $268.00Low
i
Rating by Do Kim at BMO Capital Markets
1/8/2020OppenheimerBoost Price TargetOutperform$230.00 ➝ $265.00Low
i
1/6/2020Piper Jaffray CompaniesBoost Price TargetOverweight$247.00 ➝ $284.00N/A
i
1/2/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
i
12/18/2019JPMorgan Chase & Co.Boost Price TargetOverweight$218.00 ➝ $247.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/16/2019ArgusBoost Price TargetBuy$248.00Medium
i
12/13/2019Credit Suisse GroupUpgradeBuy$231.00Low
i
Rating by Evan Seigerman at Credit Suisse Group AG
11/20/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Positive$248.00Low
i
Rating by Do Kim at BMO Capital Markets
11/19/2019CowenReiterated RatingBuyLow
i
Rating by Phil Nadeau at Cowen Inc
11/19/2019GuggenheimUpgradeNeutral ➝ Buy$252.00High
i
11/12/2019SunTrust BanksInitiated CoverageBuy$235.00Medium
i
11/4/2019Credit Suisse GroupReiterated RatingBuy$228.00Low
i
11/1/2019Maxim GroupReiterated RatingHoldHigh
i
10/31/2019Piper Jaffray CompaniesBoost Price TargetOverweight$230.00 ➝ $247.00High
i
10/22/2019Credit Suisse GroupBoost Price TargetOverweight$213.00 ➝ $221.00Low
i
10/22/2019SVB LeerinkBoost Price TargetMarket Perform$186.00 ➝ $203.00High
i
10/22/2019CitigroupBoost Price TargetBuy$205.00 ➝ $225.00High
i
10/21/2019BMO Capital MarketsSet Price TargetBuy$232.00Medium
i
Rating by Do Kim at BMO Capital Markets
10/21/2019Jefferies Financial GroupSet Price TargetBuy$220.00Medium
i
Rating by Michael Yee at Jefferies Financial Group Inc.
10/21/2019CowenSet Price TargetBuy$220.00Medium
i
Rating by Phil Nadeau at Cowen Inc
10/21/2019Robert W. BairdSet Price TargetBuy$210.00Medium
i
Rating by Brian Skorney at Robert W. Baird
10/21/2019JPMorgan Chase & Co.Set Price TargetBuy$218.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/16/2019Bank of AmericaInitiated CoverageBuy$220.00Medium
i
9/23/2019Jefferies Financial GroupBoost Price Target$210.00 ➝ $220.00Medium
i
9/6/2019Morgan StanleyBoost Price TargetOverweight$215.00 ➝ $240.00Low
i
9/3/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$226.00 ➝ $254.00High
i
8/12/2019Royal Bank of CanadaSet Price TargetBuy$213.00Low
i
Rating by Brian Abrahams at Royal Bank of Canada
8/2/2019Maxim GroupReiterated RatingHoldLow
i
8/1/2019Credit Suisse GroupBoost Price TargetOutperform$209.00 ➝ $213.00Low
i
8/1/2019Piper Jaffray CompaniesBoost Price TargetOverweight$217.00 ➝ $230.00Low
i
8/1/2019Stifel NicolausBoost Price TargetBuy$205.00 ➝ $211.00Low
i
8/1/2019JPMorgan Chase & Co.Reiterated RatingBuy$212.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/1/2019HC WainwrightReiterated RatingBuy$220.00High
i
8/1/2019Needham & Company LLCDowngradeBuy ➝ HoldHigh
i
7/31/2019CowenSet Price TargetBuy$220.00N/A
i
Rating by Phil Nadeau at Cowen Inc
6/2/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
5/23/2019The Goldman Sachs GroupReiterated RatingBuy$220.00Low
i
5/23/2019CitigroupReiterated RatingBuy ➝ Buy$205.00Low
i
5/20/2019Credit Suisse GroupInitiated CoverageOutperform$209.00 ➝ $209.00Medium
i
5/1/2019Needham & Company LLCReiterated RatingBuy$195.00Low
i
5/1/2019JPMorgan Chase & Co.Reiterated RatingBuy$209.00High
i
4/30/2019CowenReiterated RatingBuy$220.00High
i
4/11/2019Evercore ISIInitiated CoverageIn-Line$183.00Low
i
3/26/2019William BlairUpgradeMarket Perform ➝ Outperform$183.85Medium
i
Rating by Y. Xu at William Blair
3/19/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$185.40Medium
i
3/7/2019OppenheimerBoost Price TargetOutperform ➝ Outperform$200.00 ➝ $230.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/6/2019CowenReiterated RatingBuy$220.00Medium
i
3/6/2019Maxim GroupReiterated RatingHoldMedium
i
2/6/2019BMO Capital MarketsBoost Price TargetOutperform$234.00High
i
2/6/2019Maxim GroupDowngradeBuy ➝ HoldHigh
i
1/4/2019CitigroupLower Price TargetBuy ➝ Buy$206.00 ➝ $205.00Medium
i
1/2/2019Raymond JamesDowngradeOutperform ➝ Market Perform$165.71Low
i
Rating by Laura Chico at Raymond James
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$211.00 ➝ $210.00High
i
12/17/2018GuggenheimInitiated CoverageNeutralMedium
i
Rating by Whitney Ijem at Guggenheim
12/17/2018Cantor FitzgeraldReiterated RatingBuy$217.00High
i
11/27/2018OppenheimerSet Price TargetBuy$200.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/27/2018Cantor FitzgeraldReiterated RatingBuy$217.00Low
i
10/26/2018Piper Jaffray CompaniesLower Price TargetOverweight$217.00Medium
i
10/26/2018HC WainwrightUpgradeNeutral ➝ Buy$220.00High
i
10/25/2018BMO Capital MarketsLower Price TargetOutperform$204.00 ➝ $192.00High
i
10/25/2018Raymond JamesSet Price TargetBuy$211.00 ➝ $201.00High
i
Rating by Laura Chico at Raymond James
10/24/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/2/2018Raymond JamesInitiated CoverageBuyLow
i
Rating by Laura Chico at Raymond James
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$217.00Medium
i
8/28/2018ArgusBoost Price TargetBuy ➝ Average$200.00High
i
Rating by Jasper Hellweg at Argus
8/7/2018Stifel NicolausBoost Price TargetBuy$182.00 ➝ $200.00Medium
i
7/30/2018CitigroupBoost Price TargetBuy ➝ Buy$203.00 ➝ $206.00Medium
i
7/26/2018Royal Bank of CanadaReiterated RatingBuy$203.00Medium
i
7/26/2018UBS GroupBoost Price TargetNeutral ➝ Neutral$183.00 ➝ $188.00High
i
7/26/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$207.00 ➝ $211.00High
i
7/26/2018OppenheimerBoost Price TargetOutperform$180.00 ➝ $200.00High
i
7/26/2018Piper Jaffray CompaniesBoost Price TargetOverweight$230.00High
i
7/26/2018BMO Capital MarketsBoost Price TargetOutperform$204.00High
i
7/16/2018Jefferies Financial GroupBoost Price TargetBuy$210.00Low
i
7/1/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
6/12/2018ArgusSet Price TargetBuy ➝ Buy$172.00Low
i
Rating by Jasper Hellweg at Argus
4/27/2018CowenReiterated RatingBuy$200.00Low
i
4/27/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $207.00Low
i
4/27/2018Maxim GroupReiterated RatingBuy$200.00High
i
Rating by Jason McCarthy at Maxim Group
3/5/2018Maxim GroupBoost Price TargetBuy ➝ Buy$195.00 ➝ $200.00Medium
i
2/23/2018ArgusSet Price TargetBuy ➝ Buy$194.00High
i
2/13/2018JMP SecuritiesReiterated RatingMarket Outperform ➝ Outperform$200.00 ➝ $211.00Low
i
2/13/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$195.00 ➝ $196.00Low
i
2/13/2018HC WainwrightReiterated RatingHold$103.00Low
i
2/2/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$198.00 ➝ $200.00Medium
i
2/1/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$180.00 ➝ $197.00High
i
2/1/2018HC WainwrightReiterated RatingHold$103.00High
i
2/1/2018CitigroupReiterated RatingBuyHigh
i
2/1/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Buy$184.00 ➝ $191.00High
i
2/1/2018SVB LeerinkReiterated RatingOutperform$175.00 ➝ $190.00High
i
2/1/2018Royal Bank of CanadaBoost Price TargetOutperform$200.00High
i
2/1/2018Jefferies Financial GroupReiterated RatingBuy$195.00High
i
2/1/2018BarclaysBoost Price TargetOverweight ➝ Overweight$180.00 ➝ $200.00High
i
1/31/2018Maxim GroupReiterated RatingBuy$195.00Low
i
1/23/2018Bank of AmericaReiterated RatingBuy$180.00Low
i
1/9/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/5/2018Bank of AmericaUpgradeNeutral ➝ Buy$180.00Low
i
1/4/2018OppenheimerBoost Price TargetOutperform$175.00 ➝ $190.00Low
i
12/12/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$175.00High
i
12/11/2017CowenReiterated RatingBuy$200.00Low
i
10/27/2017Royal Bank of CanadaReiterated RatingBuyN/A
i
10/27/2017Needham & Company LLCReiterated RatingBuy$195.00N/A
i
Rating by Danielle Brill at Needham & Company LLC
10/27/2017Robert W. BairdReiterated RatingBuyN/A
i
10/26/2017HC WainwrightReiterated RatingHold$85.00N/A
i
10/26/2017Maxim GroupReiterated RatingBuy$195.00N/A
i
Rating by Gabrielle Zhou at Maxim Group
10/26/2017Piper Jaffray CompaniesReiterated RatingOverweight$205.00N/A
i
10/18/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$175.00 ➝ $181.00N/A
i
9/29/2017DA DavidsonInitiated CoverageBuy$200.00Low
i
9/29/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$200.00Medium
i
9/27/2017BMO Capital MarketsReiterated RatingBuyLow
i
9/17/2017Needham & Company LLCReiterated RatingBuy$195.00Low
i
Rating by Danielle Brill at Needham & Company LLC
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$175.00Low
i
8/22/2017Jefferies Financial GroupReiterated RatingBuyHigh
i
8/1/2017CowenReiterated RatingBuyMedium
i
Rating by Phil Nadeau at Cowen Inc
8/1/2017ArgusBoost Price TargetBuy$71.46 ➝ $175.00Low
i
7/27/2017BMO Capital MarketsReiterated RatingOutperform$180.00 ➝ $182.00Low
i
7/27/2017OppenheimerBoost Price TargetOutperform$150.00 ➝ $175.00Medium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/27/2017JPMorgan Chase & Co.Set Price TargetBuy$175.00 ➝ $184.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
7/27/2017Maxim GroupSet Price TargetBuy$195.00High
i
Rating by Gabrielle Zhou at Maxim Group
7/22/2017Morgan StanleyReiterated RatingOverweight$153.00 ➝ $190.00Low
i
7/21/2017Robert W. BairdReiterated RatingOutperform$136.00 ➝ $171.00Low
i
Rating by Brian Skorney at Robert W. Baird
7/21/2017Needham & Company LLCReiterated RatingBuy$155.00 ➝ $195.00Low
i
Rating by Danielle Brill at Needham & Company LLC
7/21/2017BMO Capital MarketsReiterated RatingOutperform$132.00 ➝ $180.00Low
i
7/21/2017CitigroupReiterated RatingBuy$135.00 ➝ $190.00Low
i
7/19/2017JPMorgan Chase & Co.Set Price TargetBuy$129.00 ➝ $175.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
7/19/2017Maxim GroupSet Price TargetBuy$143.00 ➝ $195.00Low
i
Rating by Jason McCarthy at Maxim Group
7/19/2017UBS GroupDowngradeBuy ➝ Neutral$135.00 ➝ $174.00High
i
7/19/2017Credit Suisse GroupBoost Price TargetOutperform$125.00 ➝ $195.00High
i
7/19/2017JMP SecuritiesReiterated RatingOutperformHigh
i
7/19/2017Raymond JamesUpgradeMarket Perform ➝ Outperform$181.00High
i
7/19/2017Piper Jaffray CompaniesBoost Price TargetOverweight$194.00High
i
7/19/2017Jefferies Financial GroupReiterated RatingBuy$155.00 ➝ $185.00High
i
7/19/2017HC WainwrightReiterated RatingHold$85.00High
i
Rating by Andrew Fein at HC Wainwright
7/19/2017Janney Montgomery ScottUpgradeNeutral ➝ Buy$98.00High
i
7/19/2017CowenUpgradeMarket Perform ➝ Outperform$105.00 ➝ $200.00High
i
Rating by Phil Nadeau at Cowen Inc
7/19/2017BarclaysUpgradeEqual Weight ➝ Overweight$115.00 ➝ $180.00High
i
7/18/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$130.00 ➝ $154.00High
i
7/10/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$155.00High
i
7/6/2017CowenReiterated RatingMarket Perform$105.00Low
i
Rating by Phil Nadeau at Cowen Inc
6/23/2017Needham & Company LLCUpgradeHold ➝ Buy$155.00Medium
i
6/22/2017SVB LeerinkReiterated RatingOutperformMedium
i
6/9/2017Jefferies Financial GroupReiterated RatingBuy$126.00Low
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
6/2/2017CIBCUpgradeMarket Perform ➝ OutperformLow
i
6/2/2017OppenheimerUpgradeMarket Perform ➝ Outperform$150.00Medium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
5/19/2017Maxim GroupSet Price TargetBuy$143.00Low
i
Rating by Jason McCarthy at Maxim Group
5/19/2017UBS GroupReiterated RatingBuy$132.00 ➝ $135.00N/A
i
5/19/2017JMP SecuritiesReiterated RatingOutperform$125.00 ➝ $127.00Low
i
5/19/2017Bank of AmericaReiterated RatingNeutral$121.00 ➝ $125.00Low
i
5/19/2017Morgan StanleyReiterated RatingOverweight$150.00 ➝ $153.00Low
i
5/2/2017Jefferies Financial GroupReiterated RatingBuy$126.00High
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
4/30/2017OppenheimerReiterated RatingHoldLow
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
4/28/2017Needham & Company LLCReiterated RatingHoldLow
i
4/28/2017Robert W. BairdBoost Price TargetOutperform$115.00 ➝ $136.00Low
i
Rating by Brian Skorney at Robert W. Baird
4/28/2017Credit Suisse GroupBoost Price TargetOutperform$108.00 ➝ $125.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
4/28/2017Maxim GroupReiterated RatingBuy$143.00High
i
Rating by Jason McCarthy at Maxim Group
4/23/2017BarclaysReiterated RatingEqual Weight$90.00 ➝ $100.00Low
i
4/4/2017Credit Suisse GroupReiterated RatingHold$108.00Medium
i
Rating by Alethia Young at Credit Suisse Group AG
4/2/2017HC WainwrightReiterated RatingNeutral$85.00Low
i
Rating by Andrew Fein at HC Wainwright
3/31/2017JMP SecuritiesReiterated RatingOutperform$115.00 ➝ $121.00Medium
i
3/31/2017Maxim GroupUpgradeHold ➝ Buy$143.00Low
i
Rating by Jason McCarthy at Maxim Group
3/30/2017CowenReiterated RatingMarket Perform$75.00Low
i
Rating by Phil Nadeau at Cowen Inc
3/29/2017CitigroupBoost Price TargetBuy$105.00 ➝ $124.00Low
i
3/29/2017Robert W. BairdReiterated RatingOutperform$115.00Low
i
Rating by Brian Skorney at Robert W. Baird
3/29/2017Credit Suisse GroupBoost Price TargetOutperform$100.00 ➝ $108.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
3/29/2017Stifel NicolausBoost Price TargetBuy$100.00 ➝ $129.00High
i
Rating by Adam Walsh at Stifel Nicolaus
3/29/2017BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$89.67 ➝ $100.00High
i
3/29/2017Jefferies Financial GroupReiterated RatingBuy$100.00High
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
3/20/2017SVB LeerinkReiterated RatingOutperformMedium
i
3/17/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$103.73 ➝ $115.00Low
i
3/14/2017ArgusReiterated RatingBuy$115.00 ➝ $92.95Low
i
3/9/2017UBS GroupInitiated CoverageBuy ➝ Buy$106.00N/A
i
3/7/2017BMO Capital MarketsReiterated RatingMarket Perform$78.00N/A
i
3/6/2017Robert W. BairdReiterated RatingOutperform$115.00N/A
i
Rating by Brian Skorney at Robert W. Baird
3/1/2017CitigroupInitiated CoverageBuy ➝ Buy$105.00N/A
i
2/27/2017OppenheimerReiterated RatingHoldN/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
2/11/2017CowenSet Price TargetHold$75.00N/A
i
Rating by Phil Nadeau at Cowen Inc
2/10/2017Robert W. BairdReiterated RatingOutperform ➝ PositiveN/A
i
Rating by Brian Skorney at Robert W. Baird
2/3/2017Maxim GroupReiterated RatingHoldN/A
i
Rating by Jason McCarthy at Maxim Group
1/26/2017HC WainwrightSet Price TargetHold$85.00N/A
i
Rating by Andrew Fein at HC Wainwright
1/26/2017Maxim GroupReiterated RatingHoldN/A
i
Rating by Jason McCarthy at Maxim Group
1/26/2017CowenReiterated RatingHold$75.00N/A
i
1/26/2017Stifel NicolausLower Price TargetBuy$108.00 ➝ $100.00N/A
i
Rating by Adam Walsh at Stifel Nicolaus
1/20/2017Needham & Company LLCReiterated RatingHoldN/A
i
1/17/2017Maxim GroupReiterated RatingHoldN/A
i
Rating by Jason McCarthy at Maxim Group
1/9/2017JMP SecuritiesDowngradeMarket PerformN/A
i
1/9/2017Robert W. BairdReiterated RatingBuy$115.00N/A
i
Rating by Brian Skorney at Robert W. Baird
1/8/2017Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
1/3/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
12/25/2016Piper Jaffray CompaniesSet Price TargetBuy$129.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
12/23/2016JMP SecuritiesReiterated RatingOutperform$103.00N/A
i
12/20/2016Credit Suisse GroupSet Price TargetBuy$100.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
12/15/2016OppenheimerInitiated CoverageMarket PerformN/A
i
12/9/2016Jefferies Financial GroupReiterated RatingBuy$102.00N/A
i
12/7/2016Janney Montgomery ScottReiterated RatingNeutral$98.00N/A
i
Rating by Debjit Chattopadhyay at Janney Montgomery Scott
11/30/2016Jefferies Financial GroupReiterated RatingBuy$102.00N/A
i
11/30/2016BMO Capital MarketsReiterated RatingMarket Perform$88.00N/A
i
11/29/2016Robert W. BairdReiterated RatingOutperform$115.00N/A
i
11/29/2016BarclaysDowngradeOverweight ➝ Equal Weight$100.00 ➝ $90.00N/A
i
11/17/2016Janney Montgomery ScottInitiated CoverageNeutral$98.00N/A
i
11/1/2016William BlairDowngradeOutperform ➝ Market Perform$105.00 ➝ $81.00N/A
i
Rating by Y. Xu at William Blair
10/28/2016Stifel NicolausReiterated RatingBuy$109.00 ➝ $108.00N/A
i
Rating by Adam Walsh at Stifel Nicolaus
10/28/2016Jefferies Financial GroupReiterated RatingBuy$105.00 ➝ $102.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
10/26/2016SVB LeerinkReiterated RatingOutperform$112.00 ➝ $111.00N/A
i
Rating by geoff porges at SVB Leerink LLC
10/26/2016BMO Capital MarketsReiterated RatingMarket Perform$87.00 ➝ $88.00N/A
i
10/24/2016HC WainwrightDowngradeBuy ➝ Neutral$155.00 ➝ $85.00N/A
i
Rating by Andrew Fein at HC Wainwright
10/21/2016Jefferies Financial GroupReiterated RatingBuy$105.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
10/12/2016Royal Bank of CanadaReiterated RatingBuyN/A
i
Rating by Michael Yee at Royal Bank of Canada
10/12/2016Jefferies Financial GroupReiterated RatingBuy$104.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
10/5/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/A
i
10/1/2016Royal Bank of CanadaReiterated RatingBuyN/A
i
Rating by Michael Yee at Royal Bank of Canada
9/30/2016Jefferies Financial GroupReiterated RatingBuy$107.00 ➝ $104.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
9/30/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by geoff porges at SVB Leerink LLC
9/30/2016Robert W. BairdReiterated RatingNeutral$128.00 ➝ $115.00N/A
i
Rating by Brian Skorney at Robert W. Baird
9/29/2016Stifel NicolausSet Price TargetBuy$109.00N/A
i
Rating by Adam Walsh at Stifel Nicolaus
9/29/2016Maxim GroupReiterated RatingHoldN/A
i
Rating by Jason McCarthy at Maxim Group
9/28/2016Credit Suisse GroupSet Price TargetBuy$110.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
9/17/2016SVB LeerinkSet Price TargetBuy$112.00N/A
i
Rating by geoff porges at SVB Leerink LLC
9/15/2016Jefferies Financial GroupReiterated RatingBuy$107.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
9/15/2016BMO Capital MarketsReiterated RatingHold$87.00N/A
i
9/15/2016SVB LeerinkReiterated RatingOutperform$113.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
9/15/2016Stifel NicolausBoost Price TargetBuy$105.00 ➝ $109.00N/A
i
9/13/2016CitigroupInitiated CoverageMarket PerformN/A
i
9/13/2016Raymond JamesInitiated CoverageMarket PerformN/A
i
8/16/2016Robert W. BairdReiterated RatingOutperform$128.00N/A
i
Rating by Brian Skorney at Robert W. Baird
8/16/2016Jefferies Financial GroupReiterated RatingBuy$107.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
8/16/2016Royal Bank of CanadaReiterated RatingBuyN/A
i
8/16/2016JMP SecuritiesReiterated RatingBuyN/A
i
8/16/2016Maxim GroupReiterated RatingHoldN/A
i
Rating by jason mccarthy at Maxim Group
8/16/2016Stifel NicolausLower Price TargetBuy$108.00 ➝ $105.00N/A
i
8/15/2016SVB LeerinkReiterated RatingOutperform$113.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
7/31/2016Jefferies Financial GroupReiterated RatingBuy$102.00 ➝ $107.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
7/31/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
7/28/2016Maxim GroupReiterated RatingHoldN/A
i
Rating by Jason McCarthy at Maxim Group
7/28/2016CowenReiterated RatingHoldN/A
i
Rating by Phil Nadeau at Cowen Inc
7/28/2016Morgan StanleyLower Price TargetOverweight$140.00 ➝ $139.00N/A
i
Rating by Matthew Harrison at Morgan Stanley
7/28/2016SVB LeerinkReiterated RatingOutperform$104.00 ➝ $113.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
7/7/2016Maxim GroupReiterated RatingHoldN/A
i
Rating by Jason McCarthy at Maxim Group
6/18/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
6/17/2016Jefferies Financial GroupReiterated RatingBuy$103.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
6/16/2016Credit Suisse GroupReiterated RatingBuyN/A
i
5/31/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
5/12/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by Matthew Harrison at Morgan Stanley
5/1/2016Robert W. BairdReiterated RatingOutperform$144.00 ➝ $128.00N/A
i
Rating by Brian Skorney at Robert W. Baird
4/28/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Geoff Porges at SVB Leerink LLC
4/28/2016Needham & Company LLCReiterated RatingHoldN/A
i
Rating by Alan Carr at Needham & Company LLC
4/28/2016HC WainwrightReiterated RatingBuy$155.00N/A
i
Rating by Andrew Fein at HC Wainwright
4/28/2016Maxim GroupReiterated RatingHoldN/A
i
Rating by Jason McCarthy at Maxim Group
4/28/2016BarclaysLower Price TargetOverweight$135.00 ➝ $110.00N/A
i
4/28/2016The Goldman Sachs GroupDowngradeBuy ➝ Neutral$109.00 ➝ $88.00N/A
i
4/28/2016Royal Bank of CanadaLower Price TargetOutperform$135.00 ➝ $115.00N/A
i
Rating by Michael Yee at Royal Bank of Canada
4/25/2016Robert W. BairdReiterated RatingBuyN/A
i
Rating by Brian Skorney at Robert W. Baird
4/17/2016CowenReiterated RatingHoldN/A
i
Rating by Phil Nadeau at Cowen Inc
4/11/2016Credit Suisse GroupLower Price TargetOutperform$143.00 ➝ $112.00N/A
i
4/10/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by Geoff Porges at SVB Leerink LLC
4/7/2016BMO Capital MarketsInitiated CoverageMarket Perform$90.00N/A
i
4/6/2016Jefferies Financial GroupLower Price TargetBuy$108.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
4/4/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
4/1/2016Stifel NicolausLower Price TargetBuy$140.00 ➝ $108.00N/A
i
Rating by Adam Walsh at Stifel Nicolaus
3/28/2016GuggenheimLower Price TargetBuy$145.00 ➝ $114.00N/A
i
3/27/2016Jefferies Financial GroupReiterated RatingBuy$116.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
3/23/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
3/23/2016The Goldman Sachs GroupLower Price TargetBuy$129.00 ➝ $106.00N/A
i
3/19/2016Royal Bank of CanadaReiterated RatingBuyN/A
i
Rating by Michael Yee at Royal Bank of Canada
3/18/2016Royal Bank of CanadaLower Price TargetOutperform$145.00 ➝ $135.00N/A
i
Rating by Michael Yee at Royal Bank of Canada
3/15/2016Bank of AmericaReiterated RatingNeutral$108.00N/A
i
3/14/2016SVB LeerinkReiterated RatingOutperform$128.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
3/11/2016Piper Jaffray CompaniesReiterated RatingOverweight$131.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
3/10/2016Maxim GroupReiterated RatingHoldN/A
i
3/8/2016SVB LeerinkReiterated RatingOutperform$131.00 ➝ $128.00N/A
i
Rating by Howard Liang at SVB Leerink LLC
3/8/2016CowenReiterated RatingMarket Perform$95.00N/A
i
2/22/2016The Goldman Sachs GroupLower Price Target$135.00 ➝ $129.00N/A
i
2/11/2016OppenheimerInitiated CoverageMarket PerformN/A
i
Rating by Wendy Lam at Oppenheimer Holdings Inc.
2/8/2016CowenReiterated RatingMarket Perform$95.00N/A
i
2/8/2016Maxim GroupReiterated RatingHoldN/A
i
2/6/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Geoff Porges at SVB Leerink LLC
2/4/2016SVB LeerinkInitiated CoverageOutperform$131.00N/A
i
2/4/2016ArgusLower Price TargetBuy$154.00 ➝ $140.00N/A
i
2/3/2016HC WainwrightReiterated RatingBuy$155.00N/A
i
Rating by Andrew Fein at HC Wainwright
2/1/2016Jefferies Financial GroupUpgradeHold ➝ Buy$142.00 ➝ $120.00N/A
i
1/30/2016Piper Jaffray CompaniesReiterated RatingOverweight$180.00 ➝ $143.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
1/28/2016Needham & Company LLCReiterated RatingHoldN/A
i
Rating by Alan Carr at Needham & Company LLC
1/28/2016JPMorgan Chase & Co.Reiterated RatingOverweight$147.00N/A
i
1/28/2016BarclaysLower Price TargetOverweight$150.00 ➝ $135.00N/A
i
1/26/2016Stifel NicolausReiterated RatingBuy$160.00N/A
i
Rating by Adam Walsh at Stifel Nicolaus
1/19/2016Credit Suisse GroupInitiated CoverageOutperform$151.00N/A
i
1/19/2016Maxim GroupReiterated RatingHoldN/A
i
1/13/2016JPMorgan Chase & Co.Reiterated RatingOverweight$153.00N/A
i
1/12/2016Needham & Company LLCReiterated RatingHoldN/A
i
Rating by Alan Carr at Needham & Company LLC
1/11/2016CowenReiterated RatingMarket Perform$110.00N/A
i
1/5/2016Piper Jaffray CompaniesReiterated RatingOverweight$180.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
12/1/2015Stifel NicolausInitiated CoverageBuy$160.00 ➝ $160.00N/A
i
11/26/2015JPMorgan Chase & Co.UpgradeNeutral ➝ OutperformN/A
i
(Data available from 11/25/2015 forward)
Vertex Pharmaceuticals logo
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $216.50
$215.13
$219.47

50 Day Range

MA: $226.39
$207.01
$276.09

52 Week Range

Now: $216.50
$197.47
$306.08

Volume

2,120,932 shs

Average Volume

1,857,723 shs

Market Capitalization

$56.30 billion

P/E Ratio

27.34

Dividend Yield

N/A

Beta

0.79